Surrozen, Inc. (NASDAQ:SRZN) VP Sells $14,642.91 in Stock

Surrozen, Inc. (NASDAQ:SRZN) VP Yang Li sold 843 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $17.37, for a total transaction of $14,642.91. Following the transaction, the vice president now owns 13,345 shares in the company, valued at $231,802.65. The trade was a 5.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Surrozen Stock Down 16.4 %

Shares of Surrozen stock opened at $14.23 on Tuesday. The stock’s fifty day moving average is $10.92 and its two-hundred day moving average is $9.90. Surrozen, Inc. has a 52 week low of $6.00 and a 52 week high of $18.17.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($2.77) by $2.33. The company had revenue of $10.00 million during the quarter. As a group, research analysts predict that Surrozen, Inc. will post -7.16 EPS for the current year.

Hedge Funds Weigh In On Surrozen

A number of hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC bought a new stake in shares of Surrozen during the second quarter valued at approximately $2,050,000. Stonepine Capital Management LLC purchased a new position in Surrozen during the 2nd quarter worth $724,000. CVI Holdings LLC purchased a new position in Surrozen during the 2nd quarter worth $711,000. Finally, Armistice Capital LLC bought a new stake in Surrozen during the 2nd quarter valued at $2,080,000. 66.57% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Guggenheim upgraded Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 target price for the company in a research report on Friday.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.